Cargando…

Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration

PURPOSE: The aim of this study was to investigate the optimal use of antiresorptive therapy in patients with metastatic cancer in terms of time to treatment initiation, switching strategy in case of skeletal-related event (SRE) or skeletal disease progression, and treatment efficacy beyond 2 years....

Descripción completa

Detalles Bibliográficos
Autores principales:	Mjelstad, AnneMarthe, Zakariasson, Gustav, Valachis, Antonis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726664/ https://www.ncbi.nlm.nih.gov/pubmed/30759277 http://dx.doi.org/10.1007/s00520-019-04676-6

Ejemplares similares

Importance of antiresorptive therapies for patients with bone metastases from solid tumors
por: Talreja, Draupadi B
Publicado: (2012)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
por: Leder, Benjamin Z
Publicado: (2018)

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs
por: Holen, I, et al.
Publicado: (2006)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen
por: Ekholm, Heidi M., et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
por: Navarro‐Gonzalez, Elena
Publicado: (2022)

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
por: Paton‐Hough, Julia, et al.
Publicado: (2018)

Cardiac risk in the treatment of breast cancer: assessment and management
por: Valachis, Antonis, et al.
Publicado: (2015)

Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
por: del Real, Alvaro, et al.
Publicado: (2022)

Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women
por: Jordan, Natasha, et al.
Publicado: (2006)

Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives
por: Zhang, Chenggui, et al.
Publicado: (2021)

Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis
por: Migliorini, Filippo, et al.
Publicado: (2022)

New Antiresorptive Therapies for Postmenopausal Osteoporosis
por: Choi, Hee-Jeong
Publicado: (2015)

Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review
por: Qayoom, I., et al.
Publicado: (2018)

Computed tomography bone density variations in oncological patients undergoing antiresorptive medication
por: Yanaguizawa, Wellington Hideaki, et al.
Publicado: (2022)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
por: Lou, Shenghan, et al.
Publicado: (2017)

Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer—A Retrospective Cohort Study of 161,492 Patients in Germany
por: Gremke, Niklas, et al.
Publicado: (2023)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

Prolonged Treatments With Antiresorptive Agents and PTH Have Different Effects on Bone Strength and the Degree of Mineralization in Old Estrogen-Deficient Osteoporotic Rats
por: Cheng, Zhiqiang, et al.
Publicado: (2009)

Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study
por: Jakob, Andreas, et al.
Publicado: (2022)

Influence of antiresorptive/antiangiogenic therapy on the surgical treatment outcomes of experimentally induced peri-implantitis lesions
por: Ramanauskaite, Ausra, et al.
Publicado: (2023)

Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy
por: Taras, Jillian, et al.
Publicado: (2014)

Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA
por: Bagi, Cedo M., et al.
Publicado: (2015)

Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice
por: Cheung, Angela M, et al.
Publicado: (2016)

Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis
por: Ota, Seiya, et al.
Publicado: (2016)

On the effect of antiresorptive drugs on the bone remodeling of the mandible after dental implantation: a mathematical model
por: Ashrafi, Mehran, et al.
Publicado: (2021)

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
por: Eastell, Richard, et al.
Publicado: (2022)

Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Costs, and Sequence in a Commercially Insured Population, 2003–2021
por: Wadhwa, Harsh, et al.
Publicado: (2023)

Antiresorptive Agents Increase the Effects of Exercise on Preventing Postmenopausal Bone Loss in Women: A Meta-Analysis
por: Zhao, Renqing, et al.
Publicado: (2015)

The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men
por: Schwarz, Peter, et al.
Publicado: (2011)

Heparanase-1 facilitates bone remodeling on bone defect animal model with optimal dosage and treatment duration
por: Wang, Jir-You, et al.
Publicado: (2020)

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo
por: Ottewell, PD, et al.
Publicado: (2006)

Medication burden of Saudi Arabian women receiving antiresorptive therapy
por: Sadat-Ali, Mir, et al.
Publicado: (2012)

Composition and Properties of Saliva in Patients with Osteoporosis Taking Antiresorptive Drugs
por: Sobczak-Jaskow, Hanna, et al.
Publicado: (2023)

The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis
por: Agarwal, Amil R., et al.
Publicado: (2023)

Bilateral retinoblastoma presenting as metastases to forearm bones four years after the initial treatment
por: Kuruva, Manohar, et al.
Publicado: (2011)

Serotonin reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local antiresorptive effect
por: Ortuño, María José, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1574otrgv7ocicvh5ra9fbd46v